December 2014

FDA Receives Submission for Hemophilia A Drug BAX 855

January 05, 2015


The US Food and Drug Administration recently announced it had received a submission for a biologics license application from Nektar Therapeutics and Baxter International Inc for an investigational, extended half-life recombinant factor VIII treatment for hemophilia A.